1 – 10 of 110
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
- Clinical impact of additional cytogenetic aberrations, cKIT and RAS mutations, and treatment elements in pediatric t(8;21)-AML: results from an international retrospective study by the International Berlin-Frankfurt-Münster study group
- 2015
- Toxicities and doses of chemotherapy drugs in hyperthermic intraperitoneal chemotherapy (HIPEC)
- Identification of a predictive signature based on immunohistochemical (IHC), RNA-seq and epigenetic profiling of melanoma metastases for response to ipilimumab-based immunotherapy
- Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20⁺ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study
- Evaluation of abiraterone acetate post-docetaxel in the Belgian compassionate use program
- Collaborative efforts driving progress in pediatric acute myeloid leukemia
- Effect of sunitinib treatment on mutations and methylation in metastatic renal cancer
- Acute toxicity and early quality of life after dose intensified salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: first results of the randomized trial SAKK 09/10
- Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 good respons randomized controlled trial
- 2014
- Epigenetic profiling of prostate cancer tissue to identify men with high-risk disease